STOK240920C5000
- 9.90
- 0.000.00%
Stoke Therapeutics Newsroom
Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham
Stoke Therapeutics | 10-Q: Q2 2024 Earnings Report
Promising Outlook for Stoke Therapeutics' Zorevunersen as a Disease-Modifying Therapy in Dravet Syndrome
Buy Rating Reaffirmed for Stoke Therapeutics Amidst Clinical Progress and Strong Financial Footing
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Express News | FDA Removes Partial Clinical Hold On Zorevunersen (STK-001) As Stoke Therapeutics Advances Toward A Phase 3 Registrational Study Of Zorevunersen In Children And Adolescents With Dravet Syndrome
Express News | Stoke Therapeutics Q2 2024 GAAP EPS $(0.46) Beats $(0.56) Estimate, Sales $4.80M Beat $3.26M Estimate
Express News | Stoke Therapeutics: On Track to Provide Regulatory Update on Phase 3 Registrational Plans for Zorevunersen in H2
Express News | Stoke Therapeutics Inc: FDA Has Removed Partial Clinical Hold on Zorevunersen
Express News | Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Express News | Stoke Therapeutics Q2 Operating Expenses USD 34.173 Million
Express News | Stoke Therapeutics Q2 Basic EPS USD -0.46
Express News | Stoke Therapeutics Q2 Net Income USD -25.695 Million Vs. IBES Estimate USD -28.9 Million
Stoke Therapeutics 2Q Rev $4.83M >STOK
Stoke Therapeutics (NASDAQ:STOK) Pulls Back 8.8% This Week, but Still Delivers Shareholders Stellar 136% Return Over 1 Year
The 17% Return This Week Takes Stoke Therapeutics' (NASDAQ:STOK) Shareholders One-year Gains to 151%
Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $17
Express News | Wedbush Reiterates Outperform on Stoke Therapeutics, Maintains $17 Price Target